<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1619</td>
<td>Highlights of This Issue</td>
<td></td>
</tr>
<tr>
<td>1621</td>
<td><strong>EDITORIAL</strong></td>
<td></td>
</tr>
<tr>
<td>1621</td>
<td>Toward a New Era in Cancer Treatment: Message from the New Editor-in-Chief</td>
<td>John C. Reed</td>
</tr>
<tr>
<td>1623</td>
<td><strong>SPOTLIGHT IN CLINICAL RESPONSE</strong></td>
<td></td>
</tr>
<tr>
<td>1623</td>
<td>Sustained Remission of Multicentric Castleman Disease in Children Treated with Tocilizumab, an Anti-Interleukin-6 Receptor Antibody</td>
<td>Caroline Galeotti, Adeline Boucheron, Séverine Guillaume, and Isabelle Kone-Paut</td>
</tr>
<tr>
<td>1627</td>
<td><strong>REVIEW</strong></td>
<td></td>
</tr>
<tr>
<td>1627</td>
<td>DNA Damage Repair Pathways in Cancer Stem Cells</td>
<td>Marcello Maugeri-Saccà, Monica Bartucci, and Ruggero De Maria</td>
</tr>
<tr>
<td>1637</td>
<td><strong>THERAPEUTIC DISCOVERY</strong></td>
<td></td>
</tr>
<tr>
<td>1637</td>
<td>SAR131675, a Potent and Selective VEGFR-3–TK Inhibitor with Antilymphangiogenic, Antitumoral, and Antimetastatic Activities</td>
<td>Antoine Alam, Isabelle Blanc, Geneviève Gueguen-Dorbes, Olivier Duclos, Jacques Bonnin, Pauline Barron, Marie-Claude Laplace, Gaelec Morin, Florence Gaujarengues, Frédérique Dol, Jean-Pascal Hérault, Paul Schaeffer, Pierre Savi, and Françoise Bono</td>
</tr>
<tr>
<td>1661</td>
<td><strong>Cotargeting Stress-Activated Hsp27 and Autophagy as a Combinatorial Strategy to Amplify Endoplasmic Reticular Stress in Prostate Cancer</strong></td>
<td>Masafumi Kumanu, Junya Furukawa, Masaki Shiota, Anousheh Zardan, Fan Zhang, Eliana Beraldi, Romina M. Wiedmann, Ladan Fazli, Amina Zoubeidi, and Martin E. Gleave</td>
</tr>
<tr>
<td>1672</td>
<td>A Small-Molecule Inhibitor of Glucose Transporter 1 Downregulates Glycolysis, Induces Cell-Cycle Arrest, and Inhibits Cancer Cell Growth In Vitro and In Vivo</td>
<td>Yi Liu, Yanyan Cao, Weihe Zhang, Stephen Bergmeier, Yannrong Qian, Huizook Akbar, Robert Colvin, Juan Ding, Lingying Tong, Shiying Wu, Jennifer Hines, and Xiaohou Chen</td>
</tr>
<tr>
<td>1683</td>
<td><strong>TARGETING SUBCELLULAR LOCALIZATION THROUGH THE POLO-BOX DOMAIN: NON-ATP COMPETITIVE INHIBITORS RECAPITULATE A PLK1 PHENOTYPE</strong></td>
<td>Campbell Mchne, Kara Estes, Merissa Baxter, Zhengguan Yang, Doaa Boshra Farag, Paul Johnston, John S. Lazo, Jianjun Wang, and Michael D. Wyatt</td>
</tr>
<tr>
<td>1693</td>
<td><strong>NEW USE FOR AN OLD DRUG: INHIBITING ABCG2 WITH SORAFENIB</strong></td>
<td>Yinxiang Wei, Yuanfang Ma, Qing Zhao, Zhiguan Ren, Yan Li, Tingjun Hou, and Hui Peng</td>
</tr>
<tr>
<td>1703</td>
<td><strong>GROWTH INHIBITION OF OVARIAN TUMOR-INITIATING CELLS BY NICLOSAMIDE</strong></td>
<td>Yi-Te Yo, Ya-Wen Lin, Yu-Chi Wang, Curt Balch, Rui-Lan Huang, Michael W.Y. Chan, Huey-Kang Sytwu, Chi-Kuan Chen, Cheng-Chang Chang, Kenneth P. Nephew, Tim Huang, Mu-Hsien Yu, and Hung-Cheng Lai</td>
</tr>
</tbody>
</table>
PRECLINICAL DEVELOPMENT

1713  
REST Is a Novel Prognostic Factor and Therapeutic Target for Medulloblastoma  
Pete Taylor, Jason Fangusaro, Veena Rajaram, Stewart Goldman, Irene B. Helenowski, Tobey MacDonald, Martin Hasselblatt, Lars Riedemann, Alvano Laureano, Laurence Cooper, and Vidya Gopalakrishnan

1724  
Pharmacogenomic Profiling and Pathway Analyses Identify MAPK-Dependent Migration as an Acute Response to SN38 in p53 Null and p53-Mutant Colorectal Cancer Cells  

1735  
Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaaneplanocin A with Gemcitabine in Pancreatic Cancer Cells  
Amir Avan, Francesco Crea, Elisa Paolicchi, Nicola Funel, Elena Galvani, Victor E. Marquez, Richard J. Honeywell, Romano Danesi, Godefridus J. Peters, and Elisa Giovannetti

1747  
Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations  

1758  
Targeting the PI3K/mTOR Axis, Alone and in Combination with Autophagy Blockade, for the Treatment of Malignant Peripheral Nerve Sheath Tumors  

1770  
Sorafenib Inhibits Many Kinase Mutations Associated with Drug-Resistant Gastrointestinal Stromal Tumors  
Michael C. Heinrich, Adrian Marino-Enriquez, Aija Presnell, Rachel S. Donsky, Diana J. Griffith, Arin McKinley, Janice Patterson, Takahiro Taguchi, Cher-Wei Liang, and Jonathan A. Fletcher

1781  
The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53-Mutated Multiple Myeloma Cells  
Heather J. Landau, Samuel C. McNeely, Jayasree S. Nair, Raymond L. Comenzo, Takashi Asai, Hillel Friedman, Suresh C. Jhanwar, Stephen D. Nimer, and Gary K. Schwartz

1789  
Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K  
Joanne M. Munck, Michael A. Batey, Yan Zhao, Helen Jenkins, Caroline J. Richardson, Celine Cano, Michele Tavecchio, Jody Barbeau, Julia Bardos, Liam Cornell, Roger J. Griffin, Keith Meneau, Andrew Slade, Pia Thommes, Niall M.B. Martin, David R. Newell, Graeme C.M. Smith, and Nicola J. Curtin

1799  
The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models  

1809  
CTLA-4 Blockade Expands Infiltrating T Cells and Inhibits Cancer Cell Repopulation during the Intervals of Chemotherapy in Murine Mesothelioma  
Licun Wu, Zhihong Yun, Tetsuzo Tagawa, Licun Wu, Zhihong Yun, Tetsuzo Tagawa, Katinka Rey-McIntyre, and Marc de Perrot
MOLECULAR MEDICINE IN PRACTICE

1820

Phase I Study of Pazopanib in Combination with Paclitaxel and Carboplatin Given Every 21 Days in Patients with Advanced Solid Tumors
Howard A. Burris III, Afshin Dowlati, Rebecca A. Moss, Jeffrey R. Infante, Suzanne F. Jones, David R. Spigel, Kelly T. Levinson, Diana Lindquist, Shelby D. Gainer, Mohammed M. Dar, A. Benjamin Suttle, Howard A. Ball, and Antoinette R. Tan

1829

Inhibition of Dendritic Cell Maturation by the Tumor Microenvironment Correlates with the Survival of Colorectal Cancer Patients following Bevacizumab Treatment
Adriana J. Michielsen, Sinead Noonan, Petra Martin, Miriam Tosetto, Joseph Marry, Monika Biniecka, Aoife A. Maguire, John M. Hyland, Kieran D. Sheahan, Diarmuid P. O’Donoghue, Hugh E. Mulcahy, David Fennelly, Elizabeth J. Ryan, and Jacintha N. O’Sullivan

ABOUT THE COVER

The polo-box domain (PBD) has critical roles in the mitotic functions of PLK1. Fragment ligated inhibitory peptides (FLIP) were generated with comparable affinity to peptide PBD inhibitors and possess antiproliferative phenotypes in cells consistent with the observed decrease in PLK1 centrosomal localization. FLIPs induced monopolar and multipolar spindles, in contrast to previously reported small molecule PBD inhibitors that display phenotypes only partially representative of PLK1 knockdown. PBD inhibitors retain high specificity for PLK1 over PLK3 and show the promise of non-ATP competitive kinase inhibitors as antitumor therapeutics. For details, see the article by McInnes and colleagues on page 1683.